Last reviewed · How we verify

Ropivacaine + Dexmedetomidine

Sahiwal medical college sahiwal · FDA-approved active Small molecule

Ropivacaine blocks sodium channels to provide local anesthesia, while dexmedetomidine activates alpha-2 adrenergic receptors to produce sedation and analgesia.

Ropivacaine blocks sodium channels to provide local anesthesia, while dexmedetomidine activates alpha-2 adrenergic receptors to produce sedation and analgesia. Used for Regional anesthesia and analgesia for surgical procedures, Peripheral nerve blocks, Epidural and spinal anesthesia with enhanced sedation.

At a glance

Generic nameRopivacaine + Dexmedetomidine
Also known asSupravlavicular Brachial Plexus Block with Ropivacaine and Dexmedetomidine, experimental, selective alpha 2 (α2) adrenergic agonist
SponsorSahiwal medical college sahiwal
Drug classLocal anesthetic + alpha-2 adrenergic agonist combination
TargetVoltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that inhibits sodium influx in nerve fibers, preventing depolarization and conduction of nerve impulses. Dexmedetomidine is a selective alpha-2 adrenergic agonist that enhances sedation, analgesia, and anxiolysis through central nervous system effects. The combination provides enhanced regional anesthesia with improved sedation and pain control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: